|Articles|September 21, 2020

Designing a Study to Investigate Gum Disease Associated Inflammation in SARS-CoV-2 Infection

Dr. Shervin Molayem, DDS, continues our discussion on his recent paper The Mouth-COVID Connection: Il-6 Levels in Periodontal Disease — Potential Role in COVID-19-Related Respiratory Complications.

Can gum disease worsen the severity of COVID-19? According to a recent paper published in the Journal of the California Dental Association, the answer may lie in an inflammatory marker known as Interleukin (IL) -6.

The lead author of the paper was Dr. Shervin Molayem.

Molayem is a periodontist who graduated from UCLA School of Dentistry. Shervin also completed a 3-year specialty program for periodontics, dental implants and reconstructive surgery at USC School of Dentistry.

He went on to become the founder of both the UCLA and USC Journals of Dental Research, and has conducted extensive research in the field of dental implants.

In this discussion with Contagion, Molayem outlines the possible connection between oral health, IL-6, and the severity of COVID-19 infections.

The study proposes that because of the inflammation involved in gum disease, poor oral hygiene could make one more likely to suffer complications from coronavirus infection.

In this second half of the discussion, Molayem explains how the theory can concretely be tested at the point of care with coronavirus patients.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.